VEGF is indirectly associated with NO production and acutely increases in response to hyperglycaemia

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 967-973

  Siervo, Mario ^a   Tomatis, Virginia ^b   Stephan, Blossom C M ^c   Feelisch, Martin ^d   Bluck, Les J C ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Hyperglycaemia; Nitric oxide; Obesity; Vascular endothelial growth factor

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; NITRATE; NITRIC OXIDE; TRIACYLGLYCEROL; VASCULOTROPIN;

ADULT; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; BODY COMPOSITION; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; ISOTOPE LABELING; LABORATORY DIAGNOSIS; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; STEADY STATE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MODELS, THEORETICAL; NITRIC OXIDE; OBESITY; TRIGLYCERIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84865182471     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02684.x     Document Type: Article

References (29)

1. Birk DM, Barbato J, Mureebe L, Chaer RA. Basic science review: current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular Surg 2009;42:517-30.
2. Cao Y. Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov 2010;9:107-15.
3. Kimura K, Hashiguchi T, Deguchi T, Horinouchi S, Uto T, Oku H et al. Serum VEGF--as a prognostic factor of atherosclerosis. Atherosclerosis 2007;194:182-8.
4. Loebig M, Klement J, Schmoller A, Betz S, Heuck N, Schweiger U et al. Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. PLoS ONE 2010;5:e12610.
5. Siervo M, Ruggiero D, Sorice R, Nutile T, Aversano M, Stephan BC et al. Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. J Intern Med 2010;268:338-47.
6. Siervo M, Ruggiero D, Sorice R, Nutile T, Aversano M, Iafusco M et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition 2012;28(3):262-6.
7. Siervo M, Stephan BC, Feelisch M, Bluck LJ. Measurement of in vivo nitric oxide synthesis in humans using stable isotopic methods: a systematic review. Free Radic Biol Med 2011;51:795-804.
8. Siervo M, Jackson SJ, Bluck LJ. In-vivo nitric oxide synthesis is reduced in obese patients with metabolic syndrome: application of a novel stable isotopic method. J Hypertens 2011;29:1515-27.
9. Siervo M, Bluck LJC. In vivo nitric oxide synthesis, insulin sensitivity and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome. Metabolism 2011;doi. org/10.1016/j.metabol.2011.10.003.
10. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
11. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
12. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol Endocrinol Metab 1979;236:E667-77.
13. Jackson S, Siervo M, Persson E, McKenna LM, Bluck LJC. A novel derivative for the assessment of urinary and salivary nitrate using gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008;22:4158-64.
14. Jackson SJ, Waterhouse JS, Bluck LJC. A single glucose derivative suitable for gas chromatography/mass spectrometry and gas chromatography/combustion/isotope ratio mass spectrometry. Rapid Commun Mass Spectrom 2007;21:3123-8.
15. Conover WJ, Iman RL. Analysis of covariance using the rank transformation. Biometrics 1982;38:715-24.
16. Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol 2003;50:49-59.
17. Barylski M, Kowalczyk E, Banach M, Ciecwierz J, Pawlicki L, Kowalski J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology 2009;60:87-92.
18. Vyzantiadis T, Karagiannis A, Douma S, Harsoulis P, Vyzantiadis A, Zamboulis C. Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin Exp Hypertens 2006;28:603-9.
19. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005;29:1308-14.
20. Tsai WC, Li YH, Huang YY, Lin CC, Chao TH, Chen JH. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin Sci (Lond) 2005;109:39-43.
21. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004;53:550-5.
22. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002;102:187-94.
23. Doupis J, Rahangdale S, Gnardellis C, Pena SE, Malhotra A, Veves A. Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines, and growth factors. Obesity (Silver Spring) 2011;19:729-35.
24. Valabhji J, Dhanjil S, Nicolaides AN, Elkeles RS, Sharp P. Correlation between carotid artery distensibility and serum vascular endothelial growth factor concentrations in type 1 diabetic subjects and nondiabetic subjects. Metabolism 2001;50:825-9.
25. Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study Atherosclerosis 2009;206:265-9.
26. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
27. Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464:917-21.
28. Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, Duran C et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008;81:56-60.
29. Dullaart RP, Oomen PH, Sluiter WJ. Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus. Eur J Intern Med 2007;18:193-5.